SCHEMBL634548

SCHEMBL634548

CC(Br)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 3/20 0.47
GSK3B P49841 2/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
TRPA1 O75762 2/20 0.46
MAPT P10636 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
SRD5A2 P31213 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
MDM2 Q00987 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417147 0.83 TRPA1 (0.47) CES2CES1ALOX15TSHRALDH1A1
SCHEMBL2358091 0.83 CYP2C9 (0.50) MEN1LMNAKMT2AALDH1A1GSK3B
SCHEMBL2625462 0.82 CES2 (0.54) CES2CES1ALOX15TSHRLMNA
SCHEMBL20995299 0.82 CES2 (0.54) CES2CES1ALOX15TSHRMEN1
SCHEMBL3424507 0.82 GSK3B (0.61) CES2CES1ALOX15TSHRMEN1
SCHEMBL4104106 0.81 ALDH1A1 (0.51) CES2CES1ALOX15MEN1LMNA
SCHEMBL634337 0.80 CES2 (0.52) CES2CES1MEN1LMNAKMT2A
SCHEMBL20703078 0.80 CES2 (0.52) CES2CES1MEN1LMNAKMT2A
SCHEMBL633160 0.80 ALDH1A1 (0.52) CES2CES1MEN1LMNAKMT2A
SCHEMBL2818719 0.80 CA1 (0.50) CES2ALOX15LMNAALDH1A1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 US disclosed
CN-114835688-B Substituted 4-aryl imidazole-2-ketone derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-08-06 CN disclosed
CN-117580824-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-02-20 CN disclosed
EP-3512842-B1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS INC (US) 2024-01-17 EP disclosed
EP-4237413-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2023-09-06 EP disclosed
CN-114835687-B AhR inhibitors 北京华森英诺生物科技有限公司 2023-09-05 CN disclosed
US-11584743-B2 Indole derivatives as estrogen receptor degraders ARVINAS OPERATIONS, INC. (US) 2023-02-21 US disclosed
CN-114835688-A Substituted 4-aryl imidazole-2-ketone derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-08-02 CN disclosed
CN-114835687-A AhR inhibitors 重庆华森制药股份有限公司 2022-08-02 CN disclosed
WO-2022094244-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-05-05 WO disclosed
US-4596816-A Pharmaceuticals TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-06-24 US disclosed
EP-0151702-A2 Alpha-hydroxyketone acetals SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1985-08-21 EP disclosed
EP-0122693-A1 Antifungal di(azolyl)propanol derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-10-24 EP disclosed
US-4430334-A ANTIDEPRESSANTS, METABOLISM SYNTHELABO (FR) 1984-02-07 US disclosed
EP-0048136-A2 Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1982-03-24 EP disclosed
EP-0005783-B1 IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS BAYER AG (DE) 1981-12-30 EP disclosed
US-4283334-A DIURETICS AMERICAN CYANAMID COMPANY (US) 1981-08-11 US disclosed
US-4265898-A ANTICOAGULANTS BAYER AKTIENGESELLSCHAFT (DE) 1981-05-05 US disclosed
US-4243670-A MICROBORICIDES; FUNGICIDES; SPORICIDES; HYGIENE BAYER AKTIENGESELLSCHAFT (DE) 1981-01-06 US disclosed
EP-0005783-A1 Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments BAYER AG (DE) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584743-B2 Indole derivatives as estrogen receptor degraders ESR1, GPER1, ESR2 CES2 1038/4885CES1 1371/4885ALOX15 1790/4885
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 CES2 2410/4885CES1 1563/4885ALOX15 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.